Ibrutinib Combined with Venetoclax for CLL Treatment - 4-Year Follow-Up

Chronic Lymphocytic Leukemia | Key Presentations on CLL from Recent Major ConferencesПодробнее

Ibrutinib plus venetoclax for first-line treatment of CLL: 4-year follow-up dataПодробнее

Venetoclax and ibrutinib therapy shows favourable results in the treatment of R/R CLLПодробнее

Long Term Follow-Up With Ibrutinib + Venetoclax to Treat Chronic Lymphocytic LeukemiaПодробнее

Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLLПодробнее

Updates in CLL - 2023 Best of Hematology ConferenceПодробнее

Ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukaemia (CLL)/small lym...Подробнее

3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLLПодробнее

First-line ibrutinib and venetoclax in CLLПодробнее

Part 2 - How do I use BTKi for CLL management? - Dr. Nitin Jain, USAПодробнее

Combined acalabrutinib treatments for CLLПодробнее

What’s new in the initial management of Hodgkin lymphoma?Подробнее

Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLLПодробнее

Treatment options for the young CLL patient with deletion 17p: Do they need a different approach?Подробнее